Interim Report of a Randomized Trial Comparing Zoladex 3.6 mg Depot with Diethylstilbestrol 3 mg/day in Advanced Prostate Cancer The West Midlands Urology Research Group

Emtage, L. A.; Trethowan, C.; Hilton, C.; Kelly, Karen; Blackledge, George

doi:10.1097/00000421-198801102-00040

Cited by 9 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an open uncontrolled study of 191 patients with T3 or T4-Tumor, 4 patients (2%) got transient bone pain at therapy onset [26]. Similar transient pain was reported by 5 of 95 patients, RCT [27]. There is some speculation if hot flushes are caused by a functional CGRP after treatments [28].…”

Section: Zoladex Tm (Goserelin Acetate) As Cause?mentioning

confidence: 88%

Central Pain and Complex Motoric Symptoms after Gosarelin Therapy of Prostate Cancer

Ernst

Gericke²,

Berg

2004

The Scientific World JOURNAL

View full text Add to dashboard Cite

A 76-year-old man with prostate cancer T3N0M0 and increasing PSA was treated with goserelin three times in a half year. As soon as the first treatment, he described subjective muscle weakness. After the third treatment, he developed complex motoric symptoms and atypical central pain with a likely association to goserelin. His left arm had signs of spastic movement; pain deteriorated after relaxation. The right hand showed muscle cramps under passive movements of the left arm that were not typical for rigor. He felt aching and partial burning pain in his whole body. There were few allodynic areas, mainly in the left arm. Several treatment approaches failed and the patient died some weeks after the first contact with our pain clinic due to pneumonia.

show abstract

Section: Zoladex Tm (Goserelin Acetate) As Cause?mentioning

confidence: 88%

Central Pain and Complex Motoric Symptoms after Gosarelin Therapy of Prostate Cancer

Ernst

Gericke²,

Berg

2004

The Scientific World JOURNAL

View full text Add to dashboard Cite

show abstract

“…goseralin), either alone or in combination. They are superior to diethylstilboestrol in achieving only tumour response without causing serious complications (Emtage et al, 1988) and are alternatives to orchidectomy in lowering testosterone to castrate level with the resulting tumour regression (Ryan and Peeling, 1988).…”

Section: Discussionmentioning

confidence: 99%

Prostatic metastases in the nose and paranasal sinuses

Saleh

O’Flynn²,

Jones³

1993

J. Laryngol. Otol.

View full text Add to dashboard Cite

show abstract

“…12,13 Subsequent trials have shown that DES at 3 mg/day is equivalent to other treatment options in overall survival rates. [17][18][19][20][21] However, cardiovascular toxicity with events including myocardial infarction, deep vein thrombosis, edema, and transient ischemic attack was observed in 8%-33% of patients. Gynecomastia was also significantly seen in patients with 3 mg/day DES.…”

Section: Diethylstilbestrol (Des)mentioning

confidence: 99%